CAL
VVOS icon

Capital Advisors Ltd’s Vivos Therapeutics VVOS Stock Holding History

Capital Advisors Ltd’s Portfolio VVOS Stock Details VVOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-7
Closed – – 1499
2023
Q2 		$0 Buy
+7
New +$69 ﹤0.01% 1562

Other funds holding VVOS

SWIG
Strategic Wealth Investment Group Louisville, Kentucky $788M AUM 14.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AF
Apexium Financial Dallas, Texas $2.06B AUM 15.96% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Capital Advisors Ltd's VVOS Position: Q3 2023 in Review

Capital Advisors Ltd sold out of Vivos Therapeutics (VVOS) in Q3 2023, closing a stake of 7 shares.

Capital Advisors Ltd first reported a position in VVOS in Q2 2023 and held it in 1 quarter. The position peaked at $0 in Q2 2023. 28 funds tracked by Wall St. Rank hold VVOS as of Q3 2023.

  • Capital Advisors Ltd reported no remaining Vivos Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Capital Advisors Ltd sold 7 Vivos Therapeutics shares in Q3 2023.
  • Capital Advisors Ltd first reported a position in Vivos Therapeutics in Q2 2023 and held it in 1 quarter.
  • Capital Advisors Ltd's Vivos Therapeutics position peaked at $0 in Q2 2023.
  • 28 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q3 2023.

Based on Capital Advisors Ltd's 13F filing for Q3 2023, filed 27 Oct 2023.